Progesterone in perimenopause: sleep, mood and weight

Progesterona en la perimenopausia: sueño, ánimo y peso

It's three in the morning and you're awake again. Not because of the kids, not because of your phone. Just awake, warm, heart running a little fast, with the sense that your body decided something without consulting you.

If you're between 42 and 53, this has a name. And it has a hormone that almost always gets left out of the conversation, because estrogen takes the microphone.

Here's the honest part: there's a large, well-run trial that missed its primary endpoint. And it still left behind a finding worth looking at squarely. Let's start there.

Educational content. Not medical advice. Eligibility is determined by medical evaluation.

The hormone that falls first

Perimenopause is the transition stage before your final period. You still have cycles, but they turn unpredictable: one short, one long, one that doesn't arrive, then a heavy one.

Almost everyone pictures this stage as a ramp — hormones easing down to zero. It isn't. Estrogen in perimenopause swings sharply up and down, sometimes to levels higher than in your twenties.

Progesterone is a different story, for a very concrete mechanical reason: your body makes it in quantity only after ovulation. It's the corpus luteum — what's left of the follicle after it releases an egg — that produces it during the second half of the cycle.

In perimenopause, cycles start appearing where there's bleeding but there was no ovulation. From the outside it looks like a normal cycle. On the inside, the second half went without its main hormone.

That's why many women notice something changed before any lab shows anything unusual. And it's why a single hormone measurement in this stage says so little: it can read normal on Tuesday and abnormal the following Tuesday.

Why a cycle hormone touches sleep

Here's the part that surprises almost everyone, and the reason this research exists at all.

Progesterone doesn't act only as progesterone. The body transforms it into other molecules, and the most studied one is called allopregnanolone. That molecule doesn't head for the uterus. It heads for the brain.

There it works as what pharmacology calls a positive allosteric modulator of the GABA-A receptor. Translated: GABA is the nervous system's "turn the volume down" signal, and allopregnanolone isn't that signal — it just makes the signal land louder.

You'll recognize that receptor even if you don't know its name. It's the same family of locks several sleep and anxiety medications work on.

So when a woman says she stopped sleeping well right at this stage, she isn't describing a coincidence or an exaggeration. She's describing a mechanism with a name, a receptor, and published literature behind it.

That said: a mechanism existing doesn't guarantee that giving it as a medication fixes the problem. That's exactly what the trials went out to measure.

Sleep: what the trials show

A meta-analysis published in The Journal of Clinical Endocrinology & Metabolism pooled the randomized trials of micronized progesterone with sleep outcomes: 9 trials, 388 participants, mostly postmenopausal women.

The results aren't a clean headline, and that's precisely what makes them useful.

Look at the confidence intervals on the last two. Total sleep time runs from −0.16 to 41.59: it grazes zero. In practice that means the effect could be large or could be nothing, and these data can't tell the difference.

The first one runs from 1.30 to 12.91 — entirely above zero. That's the only one of the three the analysis supports.

The authors add an important caveat: self-reported outcomes improved in most trials, more than the instruments showed. And they flag a factor that muddies several studies — in some, participants were also taking estradiol, and in others hot flushes improved. If you stop waking up hot, you'll sleep better; but then the credit may belong to the hot flushes rather than to sleep directly.

An earlier polysomnography trial published in the International Journal of Gynaecology and Obstetrics points in the same ambiguous direction: hormone therapy reduced arousals, and estrogen plus progesterone reduced periodic limb movements, hot flashes and nighttime bruxism — without significantly changing overall sleep quality.

The trial that missed its endpoint — and what it did find

This is the most relevant study, because it's the only large one run specifically in perimenopausal women rather than postmenopausal ones.

It was a Canadian phase III trial: double-blind, randomized, placebo-controlled. 189 perimenopausal women — not depressed, with flow within the past year, average age 50 — received 300 mg oral micronized progesterone at bedtime or placebo for three months, after a one-month untreated baseline.

The primary outcome was the third-month hot flush and night sweat score. There, the result was clear:

That's the honest headline: the primary endpoint was not met. Anyone selling you progesterone by citing this trial as proof it "works for hot flushes" is telling you half the story.

But there is a second half, and leaving it out would be dishonest too. In what the women reported about their own experience, there were differences versus placebo:

• Fewer perceived night sweats (p = 0.023).
• Better sleep quality (p = 0.005).
• Less perimenopause-related interference with daily life (p = 0.017).
• No increase in depression.
• No serious adverse events.

How do you read that without fooling yourself? Carefully. These are secondary outcomes, and when the primary one fails, secondary results generate hypotheses — not conclusions. A trial designed from the start to measure sleep, properly sized, is what's missing.

What can be said: in a three-month study of 189 women, this dose produced no serious adverse events and did not worsen mood. That safety signal is real and counts too.

Mood: what was measured and what wasn't

This is where you have to be most careful, because it's the ground where the most is promised and the least has been measured.

The Canadian trial expressly excluded women with depression. That means it can tell us nothing about whether progesterone helps a perimenopausal woman who is depressed. What it did report is that, in women without depression, it didn't make things worse — a safety result, not an efficacy one.

The mood connection that does have grounding is indirect, and runs along two paths. The first is the GABA-A receptor we covered: allopregnanolone influences circuits that also take part in anxiety. The second is simpler and probably more important: sleeping badly several nights in a row affects anyone's mood. If something improves sleep, mood usually follows.

That second path isn't a marketing trick — it's how the body works. But it's worth naming for what it is: a knock-on effect, not a direct action on mood.

Weight: the uncomfortable part

If you came to this article hoping progesterone will help with weight, this section will disappoint you. I'd rather that than the alternative.

There are no trials showing micronized progesterone causes weight loss. It isn't that the results are weak — it's that the question has barely been studied as a primary endpoint.

What has been studied is whether hormone therapy helps once you're already losing weight. A randomized trial published in Obesity followed 119 postmenopausal women aged 50 to 70 through six months of a primarily exercise-based weight-loss program, assigned to hormone therapy, raloxifene, or placebo.

The honest reading has two parts. One: the hormones didn't make the fat come off faster. Two: what did move the fat in that study was the weight-loss program itself, in all three groups.

One nuance worth not confusing. The literature does suggest estrogen influences where fat accumulates after menopause — the shift from hips toward the abdomen that many women describe. But influencing distribution is not the same as causing weight loss, and progesterone is not estrogen.

If your real goal is weight, weight has its own evidence, its own management and its own numbers. Folding it into the hormone conversation usually delays both.

What the FDA says, and what changed in November 2025

What it's approved for

Oral micronized progesterone has an approved product in the United States, with two specific indications: preventing endometrial hyperplasia in postmenopausal women with a uterus who are receiving estrogen, and treating secondary amenorrhea.

Sleep, mood and weight don't appear on that list. Using it for those purposes is off-label — legal and common in medicine, but it means the approved label does not support that use, and the decision rests entirely on the judgment of a licensed physician who knows your case.

The November 2025 change

On November 10, 2025 the FDA announced it would remove the boxed warning from menopausal hormone therapy products containing estrogen: more than twenty pills, patches and creams.

The announcement includes rewritten labels with age-specific guidance, framed around considering treatment for moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause onset. The probable-dementia warning and the recommendation to use the lowest dose for the shortest duration are also removed.

There's one exception worth knowing: the endometrial cancer warning stays for systemic estrogen-alone products — precisely the scenario progesterone exists to protect against.

And one clarification that needs saying out loud: a warning coming off the box doesn't mean the risks disappeared. It means the agency reassessed how to communicate them and who they apply to. Conversations about personal and family history remain exactly as necessary as before.

Weight, sleep and hormones: where your program fits

If anything is clear from all of the above, it's that perimenopause blends three things worth keeping separate: sleep, vasomotor symptoms, and weight. They have different causes, different evidence, and different management. Treating them as one bundle is the fastest way to resolve none of them.

Weight in particular has its own evidence — large, placebo-controlled, with published numbers. It doesn't depend on guessing which hormone is low this month.

That's why the order at SCTS1 is this. Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary. That physician is the one who decides what management makes sense in your case. Eligibility is determined by medical evaluation.

See the programs

GLP-1 programs with FDA-approved medications (Wegovy®, Foundayo™, Ozempic®) from $149/month, by telemedicine, in Spanish and English. Individual results vary.

What this evidence does NOT say

It does not say progesterone is useless for sleep. It says the evidence supports an effect on how long it takes you to fall asleep, and does not support the other two parameters measured. That's a partial result, not a rejection.

It does not say the Canadian trial proves progesterone works for hot flushes. Its primary endpoint was not met, and the authors write so themselves. The sleep and night-sweat findings are secondary and generate hypotheses.

It does not say it's dangerous. Over three months, in 189 women at 300 mg, there were no serious adverse events and no increase in depression. It also doesn't say it's safe long term for this use: there are no multi-year trials with that endpoint.

It does not say hormone therapy does nothing for weight. It says it didn't accelerate fat loss, and that it did improve some cardiometabolic markers. Those are different things.

It does not say that removing the boxed warning means hormone therapy carries no risk. It means the FDA reassessed how to communicate risk — and in fact kept a warning for systemic estrogen alone.

And it does not say your symptoms are in your head. A trial missing its endpoint doesn't erase what you're living through at three in the morning. It only means we don't yet have the answer you deserve.

Who is this NOT for?

• Anyone seeking progesterone expecting to lose weight: there's no evidence supporting that.
• Anyone planning to buy it online without a prescription or supervision. It's a prescription medication, and the dose and form matter.
• Anyone living with depression who expects this to treat it. The trial expressly excluded those women, and depression in this stage deserves its own evaluation, not a substitute.
• Anyone with a history of hormone-dependent cancer, clots, liver disease, or unexplained vaginal bleeding: all of that changes the conversation entirely.
• Anyone pregnant, trying to conceive, or breastfeeding who hasn't discussed it with their physician.
• Anyone expecting a hormone to fix sleep that's actually broken by undiagnosed sleep apnea, alcohol at night, or sustained stress. Those are worth ruling out first.

Frequently asked questions

What is perimenopause?

It's the transition stage before your final period. You still have cycles, but they turn irregular. What almost nobody explains is that it isn't a smooth hormonal decline: estrogen swings sharply up and down, while progesterone tends to fall earlier and more steadily, because it depends on ovulation — and in this stage some cycles happen without one.

Does progesterone help with sleep?

The evidence is partial, and it's worth saying so plainly. A meta-analysis published in The Journal of Clinical Endocrinology & Metabolism pooled 9 randomized trials with 388 participants. Combining four of them, micronized progesterone favored sleep onset latency — how long it takes you to fall asleep (effect size 7.10; 95% CI: 1.30 to 12.91) — but not total sleep time or sleep efficiency. Self-reported sleep outcomes improved in most trials.

Why would a cycle hormone affect sleep at all?

Because of what the body does with it. Progesterone converts into metabolites — the most studied is allopregnanolone — that act as positive allosteric modulators of the GABA-A receptor. That's the same receptor several sleep medications work on. Progesterone isn't a sleeping pill: it touches the same lock, with less force.

What happened in the large perimenopause trial?

The Canadian phase III trial randomized 189 perimenopausal women to 300 mg oral micronized progesterone at bedtime or placebo for 3 months. The primary outcome was the third-month hot flush and night sweat score, and there was no difference (rate difference −1.51; 95% CI: −3.97 to 0.95; p = 0.222). The authors acknowledge the trial was underpowered. In what participants reported, there were differences: fewer perceived night sweats (p = 0.023), better sleep quality (p = 0.005), and less perimenopause-related life interference (p = 0.017), with no increase in depression and no serious adverse events.

Does progesterone help you lose weight?

There is no evidence that it does, and the evidence that exists argues against expecting it. In a randomized trial of 119 postmenopausal women doing six months of exercise-based weight loss, hormone therapy did not increase loss of total or abdominal fat compared with placebo. Some cardiometabolic markers did improve. But the fat did not come off faster.

What is micronized progesterone approved for in the United States?

Two things: preventing endometrial hyperplasia in postmenopausal women with a uterus who are taking estrogen, and treating secondary amenorrhea. Sleep, mood and weight are not among the approved indications. Using it for those is off-label — a decision a licensed physician makes case by case.

Did the FDA really remove the black box warning?

Yes. On November 10, 2025 the FDA announced it would remove the boxed warning from menopausal hormone therapy products containing estrogen — more than 20 pills, patches and creams — with rewritten labels and age-specific guidance. One exception remains: the endometrial cancer warning stays for systemic estrogen-alone products. Removing a warning doesn't mean the risks vanished; it means the agency reassessed how to communicate them.

Do I need labs to know whether I'm in perimenopause?

In most cases the diagnosis is clinical: your age, your cycle pattern, and your symptoms. Hormones fluctuate so much in this stage that a single lab draw can read normal one day and abnormal the next week. What to check — and whether anything needs checking — is decided by a licensed physician looking at your full case.

Do you serve Spanish speakers?

Yes. All of our content and our care are available in English and Spanish.

Sources

• Prior JC, Cameron A, Fung M, et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes: a Phase III Canada-wide randomized placebo-controlled 4 month trial. Scientific Reports. 2023;13(1):9082. DOI · via PubMed
• Nolan BJ, Liang B, Cheung AS. Efficacy of Micronized Progesterone for Sleep: A Systematic Review and Meta-analysis of Randomized Controlled Trial Data. The Journal of Clinical Endocrinology & Metabolism. 2021;106(4):942-951. DOI · via PubMed
• Hachul H, Bittencourt LRA, Andersen ML, et al. Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women. International Journal of Gynaecology and Obstetrics. 2008;103(3):207-212. DOI · via PubMed
• Van Pelt RE, Gozansky WS, Wolfe P, et al. Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes. Obesity. 2014;22(4):1024-1031. DOI · via PubMed
• U.S. Food and Drug Administration. PROMETRIUM (progesterone) Capsules — prescribing information. FDA
• The Menopause Society. Comments on the FDA Announcement on Hormone Therapy. The Menopause Society
• Harvard Health Publishing. FDA removes menopause hormone therapy black box warnings. Harvard Health

Your trust is worth more than a sale.

More information →

This article is informational and is not medical advice. SCTS1 does not prescribe medications. All medical care, prescriptions and treatment plans are provided by licensed physicians through our partner platform. Eligibility is determined by a licensed provider. Oral micronized progesterone is a prescription medication approved by the FDA only for the prevention of endometrial hyperplasia in postmenopausal women receiving estrogen and for secondary amenorrhea; its use for sleep, mood or weight is off-label and is mentioned here for informational purposes only. SCTS1 does not offer or prescribe it. Individual results vary and are not guaranteed.